News Articles for Michael Thurn

Biotech company PharmAust has announced it will raise $10 million, alongside a $2 million share purchase plan.

Shares in Perth biotech company PharmAust rose by 14 per cent on Friday to 21 cents, following news Michael Thurn had been reappointed as the company’s managing director and chief executive officer.

Shares in Claremont-based PharmAust rose 5 per cent early on Friday morning, following news the company had received orphan drug designation for both monepantel and the treatment of motor neurone disease and amyotrophic lateral sclerosis.

Our board moves wrap includes Elizabeth Henson, Jon Coates, Shannon Robinson, Glenn Cooper, Grant Anderson, Greg Smith, Fergus Kiley, Keith Martens, Craig Burton, Peter Swiridiuk, Michael Thurn.

PharmAust's chief executive Michael Thurn has resigned from the Perth biotech company, triggering a drop in its share price.

Our board moves wrap includes Karl Page, Larry Marshall, Dino Otranto, Fiona Hick, Mark Barnaba, Michael Thurn, and Roger Aston.

Our board moves wrap includes Brian Thomas, Annie Guo, Peter Ingram, Michael Thurn, Jeremy Whybrow, Patrick Glovac, and Vaughn Taylor.

Our daily board moves wrap includes Michael Thurn, Deborah Ho, Torey Marshall, Simon Francis, Hayden Locke, Anthony Hall, and Jason Brewer.